Related references
Note: Only part of the references are listed.Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial
Ed Clarke et al.
LANCET INFECTIOUS DISEASES (2021)
Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance
Grant A. Mackenzie et al.
LANCET INFECTIOUS DISEASES (2021)
Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji
Eleanor F. G. Neal et al.
VACCINE (2020)
High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi
Todd D. Swarthout et al.
NATURE COMMUNICATIONS (2020)
Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study
Stefan Flasche et al.
BMC MEDICINE (2020)
Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children
Daniel M. Weinberger et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2019)
Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis
Micah Silaba et al.
LANCET GLOBAL HEALTH (2019)
Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study
Laura L. Hammitt et al.
LANCET (2019)
Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda
O. le Polain de Waroux et al.
BMC INFECTIOUS DISEASES (2018)
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1+1) compared with two primary doses and a booster (2+1) in UK infants: a multicentre, parallel group randomised controlled trial
David Goldblatt et al.
LANCET INFECTIOUS DISEASES (2018)
Long-term Impact of a 3+0 Schedule for 7-and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014
Sanjay Jayasinghe et al.
CLINICAL INFECTIOUS DISEASES (2017)
Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities
B. M. Althouse et al.
EPIDEMIOLOGY AND INFECTION (2017)
Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies
Grant A. Mackenzie et al.
LANCET INFECTIOUS DISEASES (2017)
Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study
Grant A. Mackenzie et al.
LANCET INFECTIOUS DISEASES (2016)
Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
Panchali Roy Chowdhury et al.
CLINICAL INFECTIOUS DISEASES (2015)
GAVI exceeds US$7·5 billion fundraising target
Ann Danaiya Usher
LANCET (2015)
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
Matthew R. Moore et al.
LANCET INFECTIOUS DISEASES (2015)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to pneumococcal vaccination
Jacek Wysocki et al.
VACCINE (2015)
The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Studies
Catherine Satzke et al.
PLOS MEDICINE (2015)
The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries
Stefan Flasche et al.
PLOS MEDICINE (2015)
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
Nick J. Andrews et al.
LANCET INFECTIOUS DISEASES (2014)
Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions
E. Usuf et al.
VACCINE (2014)
Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: Updated recommendations from the World Health Organization Pneumococcal Carriage Working Group
Catherine Satzke et al.
VACCINE (2013)
Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
Anneke Steens et al.
VACCINE (2013)
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
An-Wen Chan et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy
Geraldine Blanchard-Rohner et al.
EXPERT REVIEW OF VACCINES (2011)
The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule
Martin O. Ota et al.
VACCINE (2011)
Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study
Stefan Flasche et al.
PLOS MEDICINE (2011)
African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults
Bradford D. Gessner et al.
BMC INFECTIOUS DISEASES (2010)
Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
F. M. Russell et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers
Sylvia H. Yeh et al.
PEDIATRICS (2010)
Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method
Simon Rueckinger et al.
VACCINE (2010)
Effect of Reduced-Dose Schedules With 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Pneumococcal Carriage in Children A Randomized Controlled Trial
Elske J. M. van Gils et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster responsele
Geraldine Blanchard Rohner et al.
JOURNAL OF IMMUNOLOGY (2008)
Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine
Elizabeth A. Clutterbuck et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
Cynthia G. Whitney et al.
LANCET (2006)
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
FT Cutts et al.
LANCET (2005)
Share Paper
